UTHR United Therapeutics

United Therapeutics is a specialty biopharmaceutical company focused on the development and commercialization of treatments for rare, life-threatening diseases including pulmonary arterial hypertension. Sector: Healthcare.

United Therapeutics (UTHR) is an individual stock. The analysis below presents key financial metrics for the company, covering profitability, capital efficiency, valuation, margins, and growth.

Looking at how effectively the company deploy capital, ROIC is 28.63%, WACC is 9.12%, and the economic spread is 19.50%. On balance, returns on invested capital exceed the cost of funding by a comfortable margin, which over time compounds favorably for long-term holders. Supporting metrics show ROE at 19.64% and ROA at 14.94%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a company with credible compounding capacity if current operating execution persists.

On an earnings multiple basis, trailing P/E of 20.26, forward P/E of 19.81, PEG of 1.40. The gap between trailing and forward multiples is not especially wide, suggesting the market is pricing a steadier earnings path rather than a sharp near-term re-rating. At this PEG level, growth-adjusted valuation looks attractive — the market appears to be paying a reasonable price for the earnings growth embedded in estimates. A current ratio reading of 6.60 suggests the company is well-capitalized for near-term needs. Combining multiples and liquidity, the company appears adequately priced for its current earnings trajectory, with balance sheet health providing a degree of downside resilience.

Across the three margin layers, gross margin sits at 87.92%, operating margin at 47.62%, and free cash flow margin at 32.61%. The gross margin reading is exceptional — a reliable indicator of competitively advantaged businesses. Operating margins this strong typically indicate a combination of pricing power, cost discipline, and operating leverage. Free cash flow conversion is exceptional, indicating the company that are self-funding and cash-generative well above average. The margin profile is consistently healthy, a pattern often associated with durable competitive position and execution quality.

On a forward-looking basis, TTM revenue growth of 7.38% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of -0.58%, where implied returns are negative based on the present target distribution. Revenue growth and price targets are correlated but not the same — strong operations do not always translate to strong price appreciation, and vice versa. The forward return case rests on whether the company can sustain their operating trajectory long enough for analyst price targets to be reached or exceeded. The estimated 12-month price change is based on analyst consensus price target estimates, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Balancing the strengths against the areas of uncertainty, the weight of evidence favors an optimistic view with appropriate risk awareness.

The analysis above draws from quantitative data only and does not constitute personalized financial advice. Investors should conduct independent research and consider professional guidance before acting on any information presented here.